OPKO Health reports Q2 2026 revenue of $163.5M, narrows operating loss to $7.0M

Filed July 27, 2026 · Period ending July 27, 2026 · ~1 min read

Key Changes

• high

  Q2 2026 revenue rose to $163.5M from $156.8M year-over-year, driven by $29.4M in revenue recognized from Nicoya equity received under an amended RAYALDEE license agreement for Greater China, partially offset by lower services revenue following the September 2025 oncology asset sale to Labcorp.

  Exhibit 99.1 view on EDGAR →
• high

  Operating loss narrowed to $7.0M from $60.0M in Q2 2025; net loss improved to $8.4M ($0.01 per share) from $148.4M ($0.19 per share) in the prior-year quarter.

  Exhibit 99.1 view on EDGAR →
• high

  Amended Nicoya agreement grants OPKO a 15% equity stake in exchange for revised royalty and transfer pricing terms, with an initial tranche of Series A-2 Preferred Shares received and a second tranche expected in Q3 2026; the deal expands RAYALDEE's field of use in Greater China while maintaining up to $115M in milestone payments.

  Exhibit 99.1 view on EDGAR →